Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.
Financial Results:
Glenmark Pharmaceuticals Ltd reported Revenues for Q4FY25 of ₹3,256.20 Crores up from ₹3,062.96 Crore year on year, a rise of 6.31%.
Total Expenses for Q4FY25 of ₹2,887.10 Crores up from ₹2,858.51 Crores year on year, a rise of 1.0%.
Consolidated Net Profit of ₹4.38 Crores from -₹1,214.27 Crores in the same quarter of the previous year.
The Earnings per Share is ₹0.16, from -₹43.17 in the same quarter of the previous year.